AbbVie’s Venetoclax Up for Review on Aug. 23; Tecentriq’s Breast Cancer Use, 2nd Biosimilars Also on Agenda

AbbVie’s chronic lymphocytic leukemia (CLL) treatment venetoclax will come up for review by a key health ministry advisory panel on August 23. If given the go-ahead, the drug, known as Venclexta and Venclyxto overseas, will gain the official stamp of...read more